XRP Primed for Bullish Phase and Potential Surge, Analysts Predict
According to CryptoPotato, technical analyst CrediBULL Crypto predicts a bright future for XRP , despite the token lagging behind other leading cryptocurrencies. CrediBULL asserts that XRP is set to enter a bullish phase that could outshine other cryptocurrencies, citing bullish divergences on the three-day chart for both trading pairs as an indication of a potential price surge. The analyst's optimism extends to his price targets, predicting a potential surge of roughly 250% for the XRP/ BTC pair, projecting a move toward 0.0000356 BTC ($2.55).
Pseudonymous analyst Dark Defender adds weight to this bullish sentiment, stating that XRP has broken a significant resistance level this week and could ultimately lead the token to new all-time highs above $1. Dark Defender notes that 'April will be hot,' likely referring to Bitcoin's upcoming halving. Other technical analysts also believe XRP could explode above $1 before or after the halving, a crucial event for the crypto industry and the Bitcoin community. XRP's performance has lagged compared to other leading altcoins riding the bullish wave, with its price heavily influenced by Ripple's ongoing case against the SEC. The trial is scheduled for April 23, and while Ripple has won three consecutive victories in court, the crypto community eagerly awaits the outcome, which could reshape the industry in terms of crypto regulations. At press time, XRP is trading at $0.68, down 5% from its previous high of $0.72.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
